GlassScriptPhysician profile
Ritu Chandan
NPI 1710061650
$11,275.66
in general payments reported to CMS, 2019-2025
49 companies · $1,743 in 2025
The $1,743 reported for 2025 was more than what 94% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,592 · 2020: $982 · 2021: $1,881 · 2022: $1,309 · 2023: $1,933 · 2024: $1,836 · 2025: $1,743.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,512.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,511.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,420.23 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $1,223.85 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,008.92 | 2019-2025 | Jardiance, Spiriva Respimat, Stiolto Respimat |
| Abbvie INC. | $878.29 | 2020-2025 | Ubrelvy, Qulipta, Vraylar |
| Lilly USA, LLC | $846.02 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Glaxosmithkline, LLC. | $827.54 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Amgen INC. | $689.65 | 2019-2025 | Repatha, Evenity, Prolia |
| Pfizer INC. | $480.64 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $425.27 | 2019-2025 | Xifaxan |
| Janssen Pharmaceuticals, INC | $395.94 | 2019-2024 | Xarelto |
| Merck Sharp & Dohme LLC | $357.71 | 2019-2023 | Verquvo, Belsomra, Steglatro |
| Bayer Healthcare Pharmaceuticals INC. | $259.73 | 2021-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $166.18 | 2019-2024 | Trintellix |
| Sunovion Pharmaceuticals INC. | $141.99 | 2019-2022 | |
| Esperion Therapeutics, INC. | $137.99 | 2020-2021 |
Show all 49 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ritu Chandan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.